A Phase III, Multicenter, Randomized, parallel-group study to asses the efficacy and saftey of double-blind pasireotide LAR 40 mg and pasireotide LAR 60 mg versus open lable octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly.

drug protocol number

CSOM230C2402

drug sponsor

Novartis

drug study

Pasireotide

drug trial site

King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Jeddah)

drug status

Ongoing

drug phase